SG10201913099YA - Dosage and administration of non-fucosylated anti-cd40 antibodies - Google Patents
Dosage and administration of non-fucosylated anti-cd40 antibodiesInfo
- Publication number
- SG10201913099YA SG10201913099YA SG10201913099YA SG10201913099YA SG10201913099YA SG 10201913099Y A SG10201913099Y A SG 10201913099YA SG 10201913099Y A SG10201913099Y A SG 10201913099YA SG 10201913099Y A SG10201913099Y A SG 10201913099YA SG 10201913099Y A SG10201913099Y A SG 10201913099YA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- dosage
- administration
- fucosylated anti
- fucosylated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0009—Making of catheters or other medical or surgical tubes
- A61M25/0012—Making of catheters or other medical or surgical tubes with embedded structures, e.g. coils, braids, meshes, strands or radiopaque coils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0017—Catheters; Hollow probes specially adapted for long-term hygiene care, e.g. urethral or indwelling catheters to prevent infections
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/002—Packages specially adapted therefor ; catheter kit packages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0068—Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462072031P | 2014-10-29 | 2014-10-29 | |
| US201562134955P | 2015-03-18 | 2015-03-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201913099YA true SG10201913099YA (en) | 2020-02-27 |
Family
ID=55858352
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913099YA SG10201913099YA (en) | 2014-10-29 | 2015-10-29 | Dosage and administration of non-fucosylated anti-cd40 antibodies |
| SG11201702598XA SG11201702598XA (en) | 2014-10-29 | 2015-10-29 | Dosage and administration of non-fucosylated anti-cd40 antibodies |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201702598XA SG11201702598XA (en) | 2014-10-29 | 2015-10-29 | Dosage and administration of non-fucosylated anti-cd40 antibodies |
Country Status (22)
| Country | Link |
|---|---|
| US (8) | US11213584B2 (en) |
| EP (2) | EP3831847A1 (en) |
| JP (5) | JP6691113B2 (en) |
| KR (1) | KR20170072884A (en) |
| CN (2) | CN114522228A (en) |
| AU (2) | AU2015339128C1 (en) |
| BR (1) | BR112017008959A2 (en) |
| CA (1) | CA2963720A1 (en) |
| CY (1) | CY1124033T1 (en) |
| DK (1) | DK3212230T3 (en) |
| EA (1) | EA036498B1 (en) |
| ES (1) | ES2864756T3 (en) |
| HK (1) | HK1243328A1 (en) |
| HU (1) | HUE054075T2 (en) |
| IL (2) | IL299075A (en) |
| MX (1) | MX2017005152A (en) |
| PL (1) | PL3212230T3 (en) |
| PT (1) | PT3212230T (en) |
| SG (2) | SG10201913099YA (en) |
| SI (1) | SI3212230T1 (en) |
| WO (1) | WO2016069919A1 (en) |
| ZA (2) | ZA201702347B (en) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201913099YA (en) * | 2014-10-29 | 2020-02-27 | Seattle Genetics Inc | Dosage and administration of non-fucosylated anti-cd40 antibodies |
| US20210001032A1 (en) * | 2015-03-27 | 2021-01-07 | Eliaz Therapeutics, Inc. | Galectin-3 plasmapheresis therapy |
| AU2017219747B2 (en) | 2016-02-17 | 2023-09-28 | Seagen Inc. | BCMA antibodies and use of same to treat cancer and immunological disorders |
| US20170342169A1 (en) | 2016-05-27 | 2017-11-30 | Abbvie Biotherapeutics Inc. | Bispecific binding proteins |
| ES2901722T3 (en) | 2016-05-27 | 2022-03-23 | Abbvie Biotherapeutics Inc | Anti-CD40 antibodies and their uses |
| US11905331B2 (en) | 2016-11-11 | 2024-02-20 | Kumho Ht, Inc. | Antibody binding specifically to CD40 and use thereof |
| AR113862A1 (en) | 2017-12-01 | 2020-06-17 | Seattle Genetics Inc | ANTI-CD47 ANTIBODIES AND THEIR USES TO TREAT CANCER |
| EP3765018A4 (en) * | 2018-03-13 | 2022-03-02 | Hibercell, Inc. | Beta glucan and cd40 agonist combination immunotherapy |
| AU2019287765A1 (en) | 2018-06-15 | 2021-01-07 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| MA53434A (en) | 2018-08-23 | 2021-12-01 | Seagen Inc | ANTI-TIGIT ANTIBODIES |
| JP2022513624A (en) | 2018-11-23 | 2022-02-09 | ストライク ファーマ アクティエボラーグ | Bispecific conjugate |
| FR3089597B1 (en) | 2018-12-06 | 2020-11-20 | Gaztransport Et Technigaz | Sealed and thermally insulating tank |
| CA3123591A1 (en) * | 2018-12-19 | 2020-06-25 | Seagen Inc. | Controlled fucosylation of antibodies |
| US20220151983A1 (en) * | 2019-03-18 | 2022-05-19 | Score Pharma, Inc. | Compounds for inhibiting fucosylation and methods for using the same |
| MA55805A (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | METHODS OF MODULATING IMMUNE ACTIVITY |
| EP3986426A4 (en) * | 2019-06-21 | 2023-10-18 | Board of Regents, The University of Texas System | Targeting alpha3beta1 integrin for treatment of cancer and other diseases |
| US20220370418A1 (en) | 2019-09-09 | 2022-11-24 | Basilea Pharmaceutica International AG | Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases |
| JP2023509359A (en) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | Combination anticancer therapy with inducers of iron-dependent cell degradation |
| TW202206100A (en) | 2020-04-27 | 2022-02-16 | 美商西健公司 | Treatment for cancer |
| GB202008003D0 (en) | 2020-05-28 | 2020-07-15 | Quine Medical Ab | Anti-CD40 antibody |
| CA3184366A1 (en) | 2020-06-29 | 2022-01-06 | Darby Rye Schmidt | Viruses engineered to promote thanotransmission and their use in treating cancer |
| WO2022072523A1 (en) | 2020-09-30 | 2022-04-07 | Seagen Inc. | Uveal melanoma treatment using sea-cd40 |
| CA3200974A1 (en) | 2020-11-08 | 2022-05-12 | Seagen Inc. | Combination therapy |
| JP2024500847A (en) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | Chimeric antigen receptor systems with compatible receptor specificities |
| AU2022246895A1 (en) | 2021-03-31 | 2023-10-19 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| WO2022251311A1 (en) | 2021-05-25 | 2022-12-01 | Seagen Inc. | Methods of quantifying anti-cd40 antibodies |
| KR20240026507A (en) | 2021-06-29 | 2024-02-28 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | Immune cells engineered to promote thananotransmission and uses thereof |
| WO2023010080A1 (en) | 2021-07-30 | 2023-02-02 | Seagen Inc. | Treatment for cancer |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2052027T5 (en) | 1988-11-11 | 2005-04-16 | Medical Research Council | IMMUNOGLOBULINE VARIABLE DOMAIN SEQUENCE CLONING. |
| US5874082A (en) | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
| US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| AU6934600A (en) | 1999-08-27 | 2001-03-26 | Board Of Regents, The University Of Texas System | Cd40 ligand and cd40 agonist compositions and methods of use |
| WO2001024823A1 (en) | 1999-10-04 | 2001-04-12 | Chiron Corporation | Cd40 antagonist for treating psoriasis |
| JP2004505927A (en) | 2000-04-19 | 2004-02-26 | タノックス インコーポレイテッド | CD40 antagonist for the treatment of psoriasis and other inflammatory skin conditions |
| US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
| AU2002211366A1 (en) | 2000-10-02 | 2002-04-15 | Chiron Corporation | Human anti-cd40 antibodies |
| EP2009027B1 (en) | 2001-04-27 | 2014-05-21 | Kyowa Hakko Kirin Co., Ltd. | Anti-CD40 monoclonal antibody |
| AR039067A1 (en) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
| US20080199471A1 (en) | 2002-03-01 | 2008-08-21 | Bernett Matthew J | Optimized cd40 antibodies and methods of using the same |
| US20050136055A1 (en) | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
| KR100991010B1 (en) * | 2005-05-26 | 2010-10-29 | 제넨테크, 인크. | Humanized anti-cd40 antibodies and their methods of use |
| AU2006329944A1 (en) | 2005-12-09 | 2007-07-05 | Seattle Genetics, Inc. | Methods of using CD40 binding agents |
| WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| AU2008323701B2 (en) | 2007-11-07 | 2015-03-26 | Genentech, Inc | Methods and compositions for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies |
| AU2009206506B2 (en) * | 2008-01-23 | 2013-01-10 | Xencor, Inc. | Optimized CD40 antibodies and methods of using the same |
| ES2458541T3 (en) * | 2008-05-02 | 2014-05-06 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
| US20120258496A1 (en) * | 2010-09-27 | 2012-10-11 | Boehringer Ingelheim International Gmbh | Production of low fucose antibodies in h4-ii-e rat cells |
| US20130071403A1 (en) * | 2011-09-20 | 2013-03-21 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| SG10201913099YA (en) * | 2014-10-29 | 2020-02-27 | Seattle Genetics Inc | Dosage and administration of non-fucosylated anti-cd40 antibodies |
-
2015
- 2015-10-29 SG SG10201913099YA patent/SG10201913099YA/en unknown
- 2015-10-29 MX MX2017005152A patent/MX2017005152A/en unknown
- 2015-10-29 SI SI201531569T patent/SI3212230T1/en unknown
- 2015-10-29 CN CN202210123399.7A patent/CN114522228A/en active Pending
- 2015-10-29 EP EP20212733.8A patent/EP3831847A1/en active Pending
- 2015-10-29 CN CN201580059631.3A patent/CN107073118B/en active Active
- 2015-10-29 WO PCT/US2015/058108 patent/WO2016069919A1/en active Application Filing
- 2015-10-29 PT PT158548958T patent/PT3212230T/en unknown
- 2015-10-29 BR BR112017008959-9A patent/BR112017008959A2/en not_active Application Discontinuation
- 2015-10-29 DK DK15854895.8T patent/DK3212230T3/en active
- 2015-10-29 SG SG11201702598XA patent/SG11201702598XA/en unknown
- 2015-10-29 IL IL299075A patent/IL299075A/en unknown
- 2015-10-29 CA CA2963720A patent/CA2963720A1/en active Pending
- 2015-10-29 EA EA201790932A patent/EA036498B1/en unknown
- 2015-10-29 US US15/522,614 patent/US11213584B2/en active Active
- 2015-10-29 JP JP2017522840A patent/JP6691113B2/en active Active
- 2015-10-29 KR KR1020177009766A patent/KR20170072884A/en not_active IP Right Cessation
- 2015-10-29 ES ES15854895T patent/ES2864756T3/en active Active
- 2015-10-29 PL PL15854895T patent/PL3212230T3/en unknown
- 2015-10-29 EP EP15854895.8A patent/EP3212230B1/en active Active
- 2015-10-29 HU HUE15854895A patent/HUE054075T2/en unknown
- 2015-10-29 AU AU2015339128A patent/AU2015339128C1/en active Active
-
2017
- 2017-01-20 US US15/411,741 patent/US11202827B2/en active Active
- 2017-04-03 ZA ZA2017/02347A patent/ZA201702347B/en unknown
- 2017-04-04 IL IL251552A patent/IL251552B2/en unknown
-
2018
- 2018-02-27 HK HK18102794.4A patent/HK1243328A1/en unknown
-
2020
- 2020-01-06 JP JP2020000194A patent/JP6833080B2/en active Active
- 2020-09-08 JP JP2020150669A patent/JP7165166B2/en active Active
-
2021
- 2021-03-11 JP JP2021039216A patent/JP2021088609A/en not_active Withdrawn
- 2021-04-01 ZA ZA2021/02219A patent/ZA202102219B/en unknown
- 2021-04-16 CY CY20211100334T patent/CY1124033T1/en unknown
- 2021-04-20 AU AU2021202407A patent/AU2021202407A1/en active Pending
-
2022
- 2022-04-25 US US17/728,350 patent/US20220249662A1/en not_active Abandoned
- 2022-05-02 US US17/734,541 patent/US20220265822A1/en not_active Abandoned
- 2022-11-02 US US17/979,582 patent/US20230201343A1/en not_active Abandoned
- 2022-11-09 US US17/983,970 patent/US20230201344A1/en not_active Abandoned
-
2023
- 2023-07-12 JP JP2023114493A patent/JP2023126406A/en active Pending
- 2023-09-20 US US18/471,051 patent/US20240075135A1/en active Pending
- 2023-09-20 US US18/471,036 patent/US20240075134A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202102219B (en) | Dosage and administration of non-fucosylated anti-cd40 antibodies | |
| HK1257056A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
| IL259713A (en) | Anti-dr5 antibodies and methods of use thereof | |
| ZA201606630B (en) | Anti-ox40 antibodies and methods of use | |
| GB201701039D0 (en) | Vertically integrated continuous delivery of an application | |
| SI3487505T1 (en) | Administration and dosage of diaminophenothiazines | |
| RS59339B1 (en) | Valve for administration of drug fluids | |
| IL246489A0 (en) | Methods of using anti-steap1 antibodies and immunoconjugates | |
| GB201419540D0 (en) | Delivery of drugs | |
| HK1223630A1 (en) | Dosage and administration anti-egfr therapeutics -egfr | |
| ZA201701492B (en) | Pyrazolothiazole compound and medicine | |
| HRP20181406T1 (en) | Pharmaceutical dosage forms | |
| GB201612863D0 (en) | Administration and dosage of diaminophenothiazines | |
| GB201415486D0 (en) | Infusion package and method of manufature | |
| GB201409644D0 (en) | Inhalers and dosing devices for inhalers | |
| GB201409272D0 (en) | Synergistic combination of analgesic drugs |